## Abstract Many analyses of healthcare costs involve use of data with varying periods of observation and right censoring of cases before death or at the end of the episode of illness. The prominence of observations with no expenditure for some short periods of observation and the extreme skewness
Lifetime costs of lung transplantation: estimation of incremental costs
β Scribed by Petra J. van Enckevort; Marc A. Koopmanschap; Elisabeth M. Tenvergert; Albert Geertsma; Wim van der Bij; Wim J. de Boer; Frans F. H. Rutten
- Publisher
- John Wiley and Sons
- Year
- 1997
- Tongue
- English
- Weight
- 223 KB
- Volume
- 6
- Category
- Article
- ISSN
- 1057-9230
No coin nor oath required. For personal study only.
β¦ Synopsis
Despite an expanding number of centres which provide lung transplantation, information about the incremental costs of lung transplantation is scarce. From 1991 until 1995, in The Netherlands a technology assessment was performed which provided information about the incremental costs of lung transplantation. Costs in the situation with and without a transplantation programme were compared from a lifetime perspective. Because randomization was ethically inadmissible, only costs in the situation with the programme were observed. Both conventional treatment costs and costs of the transplantation programme were registered. Costs in the situation without the programme were based on the conventional treatment costs in the situation with the programme. Due to the study period of four years, long term follow-up costs were estimated. The total incremental costs per transplanted patient were estimated at Dfl 466 767 (5% discounted costs). The main part of these costs was caused by the high costs during the lifetime follow-up of the patients.
π SIMILAR VOLUMES
A randomized controlled study of propranolol for prevention of recurrent gastrointestinal bleeding in patients with cirrhosis: a final report. Hepatology 1984; 9. Valla D, Bercoff E, Manu Y, et al. Discrepancy between wedged hepatic venous pressure and portal venous pressure after acute propranolol
## Abstract We investigate how the scale of estimation in riskβadjustment models for healthβcare costs affects the covariate effect, where the scale of interest for the covariate effect may be different from the scale of estimation. As an illustrative example, we use claims data to estimate the inc